Table 2.

Timing onset of TFs and citokines mRNA expression, ADA, and clinical outcome in IFX-treated patients.

	TFsRNN°	IF-y mRNA°	IL-10 mRNA°	ADA onset°	Clinical outcome onset°
ADA+ PATIENTS (n = S)
Patient 1	6	U	U	2	30 (LOR)
Patient 2	6	2	14	22	30 (HR)
Patient 3	2	6	u	22	14 (LOR)
Patient 4	2	2	22	22	- (Tolerant)
Patient 5	ND	6	14	30	- (Tolerant)
Mean ± SEM	4 ± 1	4 ± 1	16.7 ± 2.1*	19.6 ± 4.7**	24.7 ± 5.3***
ADA– PATIENTS (n = 12)
Mean ± SEM	14.6 ± 5.5	11.1 ± 4.8	5.7 ± 1.5	–	–

HR, hypersensitivity reaction; LOR, loss of response; ND, not done; TFs, Transcription factors; U, undetectable.

^*p = 0.006 IL-10 mRNA in ADA+ vs. ADA– patients,

^**p = 0.001 ADA onset vs. IFN-y and TFs mRNA in ADA+ patients.

^***p = 0.007 Clinical outcome onset vs. IFN-y and TFs mRNA in ADA+ patients.

^°Reported data are expressed in weeks.